Skip to main content
Clinical Trials/NCT01899716
NCT01899716
Completed
Not Applicable

Exercise and Severe Depression: Clinical and Biological Analysis

Hospital de Clinicas de Porto Alegre1 site in 1 country50 target enrollmentJanuary 2008
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Hospital de Clinicas de Porto Alegre
Enrollment
50
Locations
1
Primary Endpoint
Depressive symptoms
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The study aimed to evaluate the use of exercise as a complementary strategy to treat severe major depression in inpatients.

Hypothesis: Exercise can be used as a safe and efficacious complimentary strategy in severe depressed inpatients.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
December 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Major Depressive Disorder according to M.I.N.I (DSM-IV) criteria American Psychiatry Association(1994)
  • score of 25 or more on Hamilton-17
  • not being involved in other physical activity programs during the hospitalization
  • aged between 18 and 60 years
  • being able to read, understand, and provide written informed consent

Exclusion Criteria

  • have three or more cardiovascular risk factors according to Physical Activity Readiness Questionnaire (PAR-Q)
  • are unable to exercise due other clinical condition
  • have diagnosis of Schizophrenia, Bipolar disorder or current use of alcohol or other drugs according to M.I.N.I DSM-IV criteria American Psychiatry Association(1994)
  • if they are taking beta-blocking medications

Outcomes

Primary Outcomes

Depressive symptoms

Time Frame: 2 weeks of hospitalization (14 days)

Hamilton 17 for depression

Secondary Outcomes

  • Brain-Derived Neurotrophic Factor(BDNF)(Baseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks))
  • Thiobarbituric acid reactive substances(TBARS)(Baseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks))
  • Quality of Life(Baseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks))
  • Depressive symptoms at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)(Discharge)

Study Sites (1)

Loading locations...

Similar Trials